2017 is going to be a big year for pharma, with immunotherapy set to throw the industry under the spotlight – and hopefully, for all the right reasons.
Immune System
Hailed as a ‘second chance’ for cancer patients, immunotherapy is changing the cancer conversation in a big way. We saw it in 2016, with the mainstream media dedicating plentiful column inches to the ‘miracle drug’, nivolumab.